NJ State Employees Deferred Compensation Plan’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-25,000
| Closed | -$151K | – | 538 |
|
|
2019
Q4 | $151K | Hold |
25,000
| – | – | 0.03% | 496 |
|
|
2019
Q3 | $90K | Hold |
25,000
| – | – | 0.02% | 513 |
|
|
2019
Q2 | $67K | Hold |
25,000
| – | – | 0.01% | 538 |
|
|
2019
Q1 | $74K | Hold |
25,000
| – | – | 0.01% | 526 |
|
|
2018
Q4 | $40K | Hold |
25,000
| – | – | 0.01% | 510 |
|
|
2018
Q3 | $92K | Sell |
25,000
-5,000
| -17% | -$14.9K | 0.02% | 503 |
|
|
2018
Q2 | $85K | Hold |
30,000
| – | – | 0.02% | 494 |
|
|
2018
Q1 | $111K | Hold |
30,000
| – | – | 0.02% | 464 |
|
|
2017
Q4 | $86K | Hold |
30,000
| – | – | 0.01% | 456 |
|
|
2017
Q3 | $135K | Sell |
30,000
-10,000
| -25% | -$44.4K | 0.02% | 444 |
|
|
2017
Q2 | $184K | Hold |
40,000
| – | – | 0.03% | 390 |
|
|
2017
Q1 | $168K | Hold |
40,000
| – | – | 0.03% | 372 |
|
|
2016
Q4 | $165K | Hold |
40,000
| – | – | 0.03% | 350 |
|
|
2016
Q3 | $324K | Hold |
40,000
| – | – | 0.07% | 303 |
|
|
2016
Q2 | $312K | Hold |
40,000
| – | – | 0.07% | 309 |
|
|
2016
Q1 | $328K | Hold |
40,000
| – | – | 0.07% | 304 |
|
|
2015
Q4 | $432K | Hold |
40,000
| – | – | 0.09% | 293 |
|
|
2015
Q3 | $276K | Buy |
+40,000
| New | +$326K | 0.06% | 323 |
|
NJ State Employees Deferred Compensation Plan's ACHN Position: Q1 2020 in Review
NJ State Employees Deferred Compensation Plan sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 25,000 shares — an estimated $151K sold.
NJ State Employees Deferred Compensation Plan first reported a position in ACHN in Q3 2015 and held it in 18 quarters. The position peaked at $432K in Q4 2015. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- NJ State Employees Deferred Compensation Plan reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- NJ State Employees Deferred Compensation Plan sold 25,000 Achillion Pharmaceuticals shares in Q1 2020, an estimated $151K.
- NJ State Employees Deferred Compensation Plan first reported a position in Achillion Pharmaceuticals in Q3 2015 and held it in 18 quarters.
- NJ State Employees Deferred Compensation Plan's Achillion Pharmaceuticals position peaked at $432K in Q4 2015.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q1 2020, filed 19 Jun 2020.